ABVC — ABVC BioPharma, Inc.
$0.91
$-0.05 (-5.56%)
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients.
Market Cap
$24.55M
Forward P/E
-2.1x
52-Week Range
N/A
ABVC Price History
Revenue vs. Net Income
$970K
Revenue · FY2022
Annual. Net margin is shown under each year.
Free Cash Flow
-$7.5M
FCF · FY2022
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-377.1%
ROCE · FY2022
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.5x
Assets ÷ liabilities · FY2022
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
12.3%
CapEx · FY2022
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
3.2M
Diluted shares · FY2022
Only one year of share data is available, so no change can be shown yet.
